NEW YORK, NY / ACCESSWIRE / May 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc.

Zymeworks Inc. ( NASDAQ:ZYME ) just released its latest quarterly report and things are not looking great. It was not ...

In a report released yesterday, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Zymeworks (ZYME – Research Report), with a ...

Why ZYME Could Bounce Back Before Long The heavy selling of ZYME shares appears to be in the process of exhausting itself, as indicated by its RSI reading of 27.67.

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.37 per share a year ago. These figures are ...

Zymeworks Inc. ( NASDAQ:ZYME ) just released its latest quarterly report and things are not looking great. It was not a... VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE ...

Ratings for Zymeworks ZYME were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish ...

Despite current financial losses, ZYME's strong cash position supports ongoing operations, with significant potential revenue from Zanidatamab. Zanidatamab's trial data and high revenue potential ...

Ashley Tisdale is a renowned actress — we found her favorite face mask and it's available to shop now on Amazon!

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab ...

NEW YORK, NY / ACCESSWIRE / May 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc.